Medical Analysis

Understanding Insulin-like Growth Factor 1 (IGF-1) and Somatomedin C Dynamics

Introduction to IGF-1 (Somatomedin C)

Insulin-like Growth Factor 1 (IGF-1), also known as Somatomedin C, is a hormone structurally similar to insulin. It consists of 70 amino acids and is stabilized by 3 disulfide bridges. The gene encoding for this protein, IGF1, is located on chromosome 12. IGF-1 is produced primarily in the liver, though it is also synthesized in peripheral tissues in response to stimulation by Growth Hormone (GH). This hormone plays a critical role in regulating pituitary GH production through a negative feedback mechanism.

Physiological Functions and Signaling Pathways

IGF-1 functions by binding to the IGF-1 receptor (IGFIR), a receptor tyrosine kinase, which subsequently activates the PI3K/Akt and MAPK pathways. These signaling cascades promote essential cellular processes, including cell growth, proliferation, differentiation, and survival, while simultaneously inhibiting apoptosis. In addition to its role alongside GH in promoting normal bone and tissue development, IGF-1 serves as a mediator of GH-independent anabolic responses across various tissues. Within the liver, it acts as a key regulator of mitochondrial function, oxidative stress, inflammation, and insulin sensitivity.

Pathophysiology of IGF-1

IGF-1 exerts its systemic effects via the activation of widely distributed IGF-1 receptors, allowing blood-transported IGF-1 to coordinate balanced growth among multiple tissues and organs. Conversely, autocrine or paracrine IGF-1 production can stimulate localized, unbalanced growth independently of systemic GH levels.

Clinical Significance of IGF-1 Testing

IGF-1 serves as a vital clinical marker for growth hormone activity. Because it is less pulsatile than GH, it provides a more stable and reliable measurement for clinical assessment. Its evaluation is essential for diagnosing disorders related to growth hormone, and it remains critical for normal childhood growth and the maintenance of tissues in adulthood.

Indications for IGF-1 Diagnostic Testing

Clinical indications for testing include the evaluation of short stature in children, often linked to growth hormone deficiency, or signs of excessive growth such as gigantism or acromegaly. Levels are frequently measured alongside other hormones to assess overall pituitary function, given the intimate link between GH regulation and the pituitary gland. Furthermore, the test is used to check a child’s nutritional status, as malnutrition may lower Somatomedin C levels. Finally, IGF-1 is often assessed in research and clinical trials to understand its complex role in various physiological processes and disease states.

Method of Blood Sample Collection

Patients undergoing this test are instructed to observe overnight fasting. A 3.0 ml blood sample is typically collected in a plain, red-capped tube for laboratory analysis.

Normal Reference Range of IGF-1

The following table outlines the standard reference ranges for IGF-1 based on age groups.

Causes and Implications of Low IGF-1 Levels

Low levels of IGF-1 may be caused by inadequate GH secretion by the pituitary, malnutrition, starvation, or chronic liver diseases such as cirrhosis or liver failure. Endocrine disorders like hypopituitarism, hypothyroidism, and adrenal insufficiency can also lower levels. Genetic disorders, such as Laron syndrome (involving mutations in GH receptor or IGF-1 genes), and the prolonged use of corticosteroid medications are also known causes. Additionally, IGF-1 levels tend to decline gradually with natural aging. The clinical implications of low IGF-1 include impaired growth and development, dwarfism, reduced bone density, decreased muscle mass and strength, and an increased risk of metabolic disorders.

Causes and Implications of High IGF-1 Levels

Elevated IGF-1 levels are associated with conditions such as acromegaly, gigantism, pituitary adenoma, and insulin resistance. Other causes include obesity, exogenous growth hormone administration, chronic kidney disease, and specific genetic factors like familial acromegaly. Certain medications, including corticosteroids and GHRH analogs, may also influence these levels. Implications of high IGF-1 include acromegaly, gigantism, increased cancer risk, cardiovascular diseases (e.g., hypertension, atherosclerosis), insulin resistance, diabetes, hypoglycemia, and musculoskeletal problems caused by bone or muscle overgrowth.

For Non-Medicos

What is IGF-1?

Insulin-like Growth Factor 1 (IGF-1), or Somatomedin C, is a hormone made mostly in your liver. It works closely with growth hormone to help your body grow, build muscle, and keep your tissues healthy. Think of it as a reliable “messenger” for growth hormone activity because it stays at steadier levels in your blood than growth hormone itself.

Why Is This Test Done?

Doctors order an IGF-1 test to understand if your growth hormone system is working properly. It is most commonly used to:

• Diagnose growth disorders like dwarfism (too little growth) or acromegaly/gigantism (too much growth).

• Check if the pituitary gland—the body’s “master” hormone gland—is functioning correctly.

• Assess a child’s nutrition, as poor nutrition can lower IGF-1 levels.

Important Test Instructions

• Fasting: You must not eat anything overnight before the blood test.

• Procedure: A nurse will collect about 3 ml of your blood using a standard tube.

Understanding Your Results

• If your levels are low: This might mean your body isn’t making enough growth hormone, or it could be due to malnutrition, liver issues, or long-term use of steroid medications. It can lead to growth delays, loss of muscle strength, or weaker bones.

• If your levels are high: This could indicate conditions like acromegaly or gigantism. It may also be linked to higher risks of diabetes, heart disease, and joint pain due to excessive tissue growth.

References:

• Clemmons, D. R. (2012). Insulin-like growth factor-1 (IGF-1) and cancer. Endocrinology and Metabolism Clinics of North America, 41(2), 263–274.

• Frystyk, J. (2010). Free insulin-like growth factors—measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Hormone & IGF Research, 20(5), 337–353.

• Giustina, A., Burman, P., Doyle, N., & Shalet, S. (2002). Consensus on criteria for cure of acromegaly: A consensus statement. Journal of Clinical Endocrinology & Metabolism, 87(11), 4918–4925.

• Growth Hormone Research Society. (2000). Consensus statement: Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH Research Society. Journal of Clinical Endocrinology & Metabolism, 85(11), 3990–3993.

• Ho, K. K. Y. (2011). Consensus workshop: Consensus diagnosis and treatment of adult GH deficiency. European Journal of Endocrinology, 165(2), 187–196.

• Juul, A. (2003). Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Hormone & IGF Research, 13(4), 113–170.

• Katznelson, L., Laws, E. R., Melmed, S., Molitch, M. E., Murad, M. H., Utz, A., & Wass, J. A. H. (2014). Acromegaly: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 99(11), 3933–3951.

• Laron, Z. (2004). Insulin-like growth factor 1 (IGF-1): A growth hormone. Molecular Pathology, 54(5), 311–316.

• LeRoith, D., & Yakar, S. (2020). Mechanisms of disease: Insulin-like growth factors in health and disease. Journal of Clinical Investigation, 130(4), 1554–1563.

• Melmed, S. (2009). Acromegaly pathogenesis and treatment. Journal of Clinical Investigation, 119(11), 3189–3202.

• Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., Shalet, S. M., & Vance, M. L. (2011). Evaluation and treatment of adult growth hormone deficiency: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 96(6), 1587–1609.

• Ranke, M. B. (2015). The role of IGF-1 in the management of growth disorders. Hormone Research in Paediatrics, 83(2), 73–81.

• Rosenfeld, R. G. (2007). Insulin-like growth factors and the GH-IGF axis in health and disease. Best Practice & Research Clinical Endocrinology & Metabolism, 21(2), 153–162.

• Yakar, S., Rosen, C. J., Beamer, W. G., Ackert-Bicknell, C. L., Wu, Y., Liu, J. L., Ohi, V. M., Faustman, E., & LeRoith, D. (2002). Circulating levels of IGF-1 directly regulate bone growth and density. Journal of Clinical Investigation, 110(6), 771–781.

• Zapf, J., Walter, H., & Froesch, E. R. (1981). Radioimmunological determination of insulin-like growth factors I and II in normal subjects and in patients with growth disorders. Journal of Clinical Investigation, 68(5), 1321–1330.

FAQ’s:

• What is IGF-1?
  It is a hormone produced primarily in the liver that promotes normal bone and tissue growth.

• What is another name?
  Insulin-like Growth Factor 1 is also referred to as Somatomedin C.

• Why measure IGF-1 levels?
  It is a stable marker of growth hormone activity, useful for diagnosing growth-related disorders.

• Is fasting required?
  Yes, patients are instructed to observe overnight fasting before having their blood sample collected.

• What tube is used?
  The 3.0 ml blood sample is collected in a plain, red-capped tube.

• What causes low levels?
  Causes include pituitary issues, malnutrition, chronic liver disease, aging, or certain genetic mutations.

• What implies high levels?
  High levels can indicate acromegaly, gigantism, pituitary adenoma, insulin resistance, or obesity.

• How does it signal?
  It binds to the IGF-1 receptor, activating pathways that promote cell growth and survival.

• Can it affect metabolism?
  Yes, in the liver, IGF-1 regulates mitochondrial function, oxidative stress, inflammation, and insulin sensitivity.

• Are there age variations?
  Yes, normal reference ranges vary significantly across different age groups, from infants to adults.

Related Diagnostic Tests

• Insulin Tolerance Test (ITT)

• Growth Hormone (GH)

• Thyroid Function Tests